Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Affiliation

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. [Email]

Abstract

To evaluate the impact of temozolomide (TMZ) introduction on the survival of patients with pituitary carcinoma (PC) compared to aggressive pituitary adenoma (APA).

Keywords

Mortality,Pituitary adenoma,Pituitary carcinoma,Temozolomide,

OUR Recent Articles